ZUG, Switzerland,August 7, 2024–MoonLake Immunotherapeutics(NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the second quarter of 2024. MoonLake ...